Moleculin reports 37% blinded remission rate in AML trial interim data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 8.40 +1.31 (18.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.09 | 52 Week High | $9.58 | |||
| Open | $7.18 | 52 Week Low | $2.34 | |||
| Day High | $8.80 | P/E | N/A | |||
| Day Low | $7.17 | EPS | $-0.34 | |||
| Volume | 102,929 | |||||
